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The number of people with diabetes and pre-diabetes are exponentially increasing. Studies on humans have shown
the beneficial effects of Zinc supplementation in patients with diabetes. The present study aims to systematically
evaluate the literature and meta-analyze the effects of Zinc supplementation on diabetes. A systematic review of
published studies reporting the effects of Zinc supplementations on diabetes mellitus was undertaken. The literature
search was conducted in the following databases; PubMed, Web of Science and SciVerse Scopus. A meta-analysis of
studies examining the effects of Zinc supplementation on clinical and biochemical parameters in patients with
diabetes was performed. The total number of articles included in the present review is 25, which included 3 studies
on type-1 diabetes and 22 studies on type-2 diabetes. There were 12 studies comparing the effects of Zinc
supplementation on fasting blood glucose in patients with type-2 diabetes. The pooled mean difference in fasting
blood glucose between Zinc supplemented and placebo groups was −18.13 mg/dl (95%CI:–33.85,–2.41; p< 0.05).
2-h post-prandial blood sugar also shows a similar distinct reduction in (−34.87 mg/dl [95%CI:–75.44; 5.69]) the Zinc
treated group. The reduction in HbA1c was −0.54 % (95%CI:–0.86;–0.21) in the Zinc treated group. There were 8
studies comparing the effects of Zinc supplementation on lipid parameters in patients with type-2 diabetes. The
pooled mean difference for total cholesterol between Zinc supplemented and placebo groups was −32.37 mg/dl
(95%CI:–57.39,–7.35; p< 0.05). Low-density lipoprotein cholesterol also showed a similar distinct reduction in the
Zinc treated group, the pooled mean difference from random effects analysis was −11.19 mg/dl (95%CI:–21.14,–1.25;
p< 0.05). Studies have also shown a significant reduction in systolic and diastolic blood pressures after Zinc
supplementation. This first comprehensive systematic review and meta-analysis on the effects of Zinc
supplementation in patients with diabetes demonstrates that Zinc supplementation has beneficial effects on
glycaemic control and promotes healthy lipid parameters. Further studies are required to identify the exact
biological mechanisms responsible for these results.
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The number of people with diabetes and pre-diabetes are
exponentially increasing worldwide due to population
growth, aging, urbanization, unhealthy eating habits, in-
creasing prevalence of obesity and physical inactivity [1].
Diabetes mellitus is a leading cause of morbidity and mor-
tality worldwide, with an estimated 346 million adults
being affected in year 2011 [2]. The prevalence is expected
to double between years 2005–2030, with the greatest* Correspondence: priyanga.ranasinghe@gmail.com
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distribution, and reproduction in any mediumincreases expected in low- and middle-income developing
countries of the African, Asian, and South American
regions [2,3]. At present, 80% of the worlds’ population
with diabetes live in low- and middle-income countries
[2,4]. Diabetes is also associated with a host of life threa-
tening and potentially disabling macro- and micro-vascular
complications [5]. Hence, there is also a much larger bur-
den in the form of lost productivity as a result of restricted
daily activity.
Ninety percent of those with diabetes have type-2 dia-
betes, characterized by insulin resistance, hyper insulinae-
mia, β-cell dysfunction and subsequent β–cell failure [6].
Insulin, is stored as a hexamer containing two Zinc ions in
β-cells of the pancreas and released into the portal venousntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ions which are co-secreted with insulin suppress inherent
amyloidogenic properties of monomeric insulin [8].
Zalewski, et al. showed that high concentrations of glucose
and other secretagogues decrease the islet cell labile Zinc
and video fluorescence analysis showed Zinc concentrated
in the islet cells was related to the synthesis, storage and se-
cretion of insulin [9]. In vitro data suggests that insulin
binds to isolated liver membranes to a greater extent and
that there is less degradation when co-administered with
Zinc [10]. Zinc is important in insulin action and carbohy-
drate metabolism [11]. Oxidative stress plays an important
role in the pathogenesis of diabetes and its’ complications.
Zinc is a structural part of key anti-oxidant enzymes such
as superoxide dismutase, and Zinc deficiency impairs their
synthesis, leading to increased oxidative stress [12]. Studies
have shown that diabetes is accompanied by hypozincemia
[13] and hyperzincuria [14]. In addition Zinc deficiency is
more common in developing countries [15], where diabetes
is also showing an exponential increase in prevalence [2].
Animal studies have shown that Zinc supplementation
improves fasting insulin level and fasting glucose in mice
[16]. Human studies have also shown the beneficial
effects of Zinc supplementation in both type-1 [17,18]
and type-2 diabetes [19,20]. However, results of isolated
randomized controlled trials are frequently contradicted
by subsequent studies [21]. Especially, in type-1 diabetes
studies have reported a negative effect of Zinc supple-
mentation on glucose homeostasis [22]. Even under the
most rigorous study design conditions, a well-planned
single study, rarely provides definitive results and chan-
ging clinical practices relying on a single high-profile
clinical trial can be harmful to patients’ health [23].
Well-designed randomized controlled trials are excellent
when looking at effectiveness, though many fall short in
reporting of safety and adverse events associated with an
intervention. Systematic reviews often have increased
power and decreased bias as compared with the individ-
ual studies they include, and the careful pooling of treat-
ment effects can provide the most accurate overall
assessment of an intervention [23]. Presently there are
no systematic reviews exploring the therapeutic efficacy
of Zinc supplementation in humans with diabetes. The
study aims to systematically evaluate the literature and
meta-analyze the effects of Zinc supplementation in
humans with diabetes and evaluate potential toxic effects




A systematic review of published studies reporting the
effects of Zinc supplementations on diabetes mellitus was
undertaken in accordance with the Preferred ReportingItems for Systematic reviews and Meta-Analyses (PRISMA)
statement for systematic reviews of interventional studies
[24]. A three staged comprehensive search of the literature
was conducted in the following databases; PubMedW (U.S.
National Library of Medicine, USA), Web of ScienceW
[v.5.4] (Thomson Reuters, USA) and SciVerse ScopusW
(Elsevier Properties S.A, USA) for studies published before
31st December 2011.
During the first stage the above databases were searched
using the following search criteria. The PubMedW database
was searched using the MeSHW (Medical Subject Head-
ings) term ‘diabetes mellitus’ and keywords ‘Zinc’, ‘Zinc
supplementation’, ‘Zn supplementation’ and ‘Zinc therapy’,
‘Zn therapy’. The Web of ScienceW database was searched
using search terms ‘diabetes mellitus’, ‘Zinc supplementa-
tion’, ‘Zn supplementation’ and ‘Zinc therapy’ ‘Zn therapy’
in article ‘topic’. In the SciVerse ScopusW database the
search terms ‘diabetes mellitus’, ‘Zinc supplementation’, ‘Zn
supplementation’ and ‘Zinc therapy’ ‘Zn therapy’ in article
‘title’, ‘abstract’ or ‘keywords’ was used as the search criteria.
Results were limited to studies on humans, published in
English. conference proceedings, editorials, commentaries
and book chapters/book reviews were excluded.
In the second stage the total hits obtained from search-
ing the databases using the above search criteria was
screened by reading the article ‘title’ and ‘abstracts’. Studies
not satisfying the inclusion criteria were excluded at this
stage. In the third stage individual manuscripts were
screened, and those not satisfying inclusion criteria were
excluded. To obtain additional data a manual search of the
reference lists of articles selected in stage three was per-
formed. Wherever possible forward citations of the studies
retrieved during the literature search was traced and
screened for possible inclusion. This search process was
conducted independently by two reviewers (PR and RJ)
and the final group of articles to be included in the review
was determined after an iterative consensus process.
Data extraction and analysis
A meta-analysis of studies examining the effects of Zinc
supplementation on the following clinical and biochemical
parameters in patients with type-2 diabetes was performed
(only 3 studies on type-1 diabetes); Fasting Blood Glucose
(FBG), 2-h Post Prandial Blood Glucose (2-h PPBS), Gly-
cated Haemoglobin (HbA1c), Total Cholesterol (TC), Low
Density Lipoprotein Cholesterol (LDL-c), High Density
Lipoprotein Cholesterol (HDL-c) and Triglycerides (TG).
A fixed effect analysis was initially conducted for all com-
parisons. Heterogeneity was assessed using the χ2 test on
Cochrane’s Q statistic [25] and by calculating I2 [26]. If sig-
nificant heterogeneity was present (p< 0.05 from χ2 test) a
random effects meta-analysis was carried out. Forest plots
were used to illustrate the study findings and meta-analysis
results. Data were analysed using RevMan version 5.1.2
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Centre, The Cochrane Collaboration, 2011) statistical soft-
ware package. In all analyses a p-value< 0.05 was consid-
ered statistically significant.
FBG, 2-h PPBS, TC, LDL-c, HDL-c and TG are reported
as mg/dl, where studies reported mmol/l a numerical con-
version to mg/dl was done based on molecular weight.
HbA1c is reported as a percentage. In studies using mul-
tiple supplements where possible the group receiving Zinc
supplementation alone was compared with placebo group
[27]. Where Zinc was supplemented in a single group to-
gether with other supplements (minerals and vitamins) we
selected the group with the least number of additional sup-
plements to compare with the placebo group [18,28-35].
In cross-over studies the pooled estimate of Zinc and pla-
cebo groups after completion of the entire cross-over
scheme was used in the analysis [36,37].
Results
Literature search
The literature search using the above search criteria identi-
fied the following number of articles in the respectiveFigure 1 Summarized search strategy.databases; PubMedW (n= 274), Web of ScienceW (n= 116)
and SciVerse ScopusW (n= 182). Four additional articles
were identified by manually searching the reference lists
and forward citations of included papers. After removing
duplicates the total number of articles included in the
present review is twenty five, which included 3 studies on
type-1 diabetes and 22 studies on type-2 diabetes. The
search strategy is summarized in Figure 1 and a descrip-
tion of the included studies provided in Table 1. The num-
ber of patients ranged from 13 to 110, and the duration of
supplementation varied from 3 week to 5 years. There
were nine studies where Zinc was used in a single group
together with other vitamins and minerals [18,28-35], in
all other studies Zinc was supplemented alone.
Effects on glycaemic control
The effects of Zinc supplementation on glycaemic con-
trol in patients with type-2 diabetes mellitus was evalu-
ated by pooling data for FBG, 2-h PPBS and HbA1C.
There were 12 studies comparing the effects of Zinc sup-
plementation on FBG in patients with Type-2 Diabetes
[19,20,28,29,33,34,36,37,40-42,47]. A forest plot of these
Table 1 Description of the included studies
Authors (reference),
year,Country




et al., [19] 2008, Iran
R, DB, P; T2DM (n = 40); age 52.7 ±
8.6 year;
2 groups; 6–12 weeks;
BMI; SBP; DBP; FBG; 2-h PPBS;
HbA1c; TG; TC; HDL-c;
LDL-c; Urea; Creatinine; ALT; AST
ZnSO4;660 mg/day
# None Reduction in TG, TC, LDL
and HbA1C
Al-Maroof
et al., [20] 2006, Iraq
R, B, P; T2DM (n = 86); age 54.6 ±
9.2 year;
2 groups; 3 months
HbA1c; FBG ZnSO4;30 mg/day* None Reduction in HbA1C
Anderson
et al., [27] 2001, Tunisia
R, DB, P; T2DM (n = 110); age 57.9 ±
6.2 year;
4 groups; 6 months
Plasma and Urinary Zinc;
Antioxidant effects
Zn gluconate;30 mg/day# Chromium Positive antioxidant effect
Blostein-Fujii
et al., [38] 1997, USA
R, B, P; T2DM (n = 60); age 60.0 ±
12.0 year;
2 groups; 3 weeks
Plasma Zinc; 5′-nucleotidase;
lipoprotein oxidation; IGF-1
30 mg/day# None Raised IGF-1
(only if low at initiation)
De Sena
et al., [39] 2005, Brazil
Case–control; T1DM (n = 37); age 4.1–
16.5 year;
2 groups; 4 months
FBG; HbA1c; Urine sugar;
Plasma and red cell Zn
7.5-15 mg/day* None Increased erythrocyte
Zinc concentration
Farvid
et al., [28] 2011, Iran
R, DB, P; T2DM (n = 67); age 52.5 ±
8.2 year;
3 groups; 4 months









Reduced severity of neuropathy
symptoms in patients with
mild-moderate neuropathy
Farvid
et al., [29] 2005, Iran
R, DB, P; T2DM (n = 69); age 50.0 ±
9.0 year;
4 groups; 3 months
Plasma and Urinary Zinc; SBP;
DBP; MAP; FBG; HbA1c; TC;





2+; Vitamin C,E Lowered urinary
albumin excretion
Farvid
et al., [30] 2004a, Iran
R, DB, P; T2DM (n = 69); age 50.3 ±
8.2 year;
4 groups; 3 months
Plasma and Urinary Zinc; SBP;
DBP; MAP
ZnSO4;30 mg/day* Mg
2+; Vitamin C,E Combination of vitamins and
minerals decreases blood pressure
Farvid
et al., [31] 2004b, Iran
R, DB, P; T2DM (n = 69); age 50.3 ±
8.2 year;
4 groups; 3 months
Plasma and Urinary Zinc; TC;
HDL-c; LDL-c; TG; Apo-A1; Apo B
ZnSO4;30 mg/day* Mg
2+; Vitamin C,E co-supplementation of Mg, Zn,
Vitamins C and E,
increases HDL and Apo-A1
Faure
et al., [17] 1995, France
Case–control; T1DM (n = 18); age 32.2 ±
8.1 year;
2 groups; 3 months
Plasma Zinc;
Antioxidant effects
Zn gluconate;30 mg/day* None Reduced lipid peroxidation
Garcia-Medina
et al., [32] 2011, Spain
R; P; T2DM (n = 97); age 54.8 ±
11.6 year;





27 mg/day* Cu2+, Mn2+, Se2+,





et al., [33] 2011, Sri Lanka
R, B, P; T2DM (n = 96); age 53.4 ±
7.2 year;
3 groups; 4 months
FBG; 2-h PPBS; HbA1c;
Creatinine; Insulin; Plasma and




Reduced HbA1C, FBG, 2-h PPBS,






















Table 1 Description of the included studies (Continued)
Gupta
et al., [40] 1998, India
R, DB, P; T2DM (n = 50); age 49.9 ±
11.0 year;
3 groups; 6 weeks
Plasma Zinc; FBG; 2-h PPBS;
Nerve conduction tests
ZnSO4;660 mg/day






R, DB, P; T2DM (n = 60); age 50.9 ±
11.1 year;
3 groups; 6 weeks
Plasma Zinc; FBG; 2-h PPBS;
Nerve conduction tests
ZnSO4;660 mg/day
# None Reduced FBG and 2 h-PPBS,
improved motor nerve
conductionvelocity
Hegazi et al., [42]
1992, Egypt
Case–control; T2DM (n = 56); age 26–
62 year;





# None Increased serum Insulin. Reduced
FBG and Glucagon
Heidarian et al., [43]
2009, Iran
R, DB, C; T2DM (n = 50); age 53.2 ±
9.2 year;




# None Reduced serum Homocysteine,
increase folate and Vitamin B12
Hussain
et al., [34] 2006, Iraq
R, DB, P; T2DM (n = 46); age 49.1 ±
6.0 year;
3 groups; 3 months
FBG; 2-h PPBS;
HbA1c;C-Peptide
Zn acetate;50 mg/day# Melatonin Reduced FBG and 2-h PPBS
Kadhim et al., [35]
2006, Iraq
R, DB, P; T2DM (n = 46); age 49.1 ±
6.0 year;
3 groups; 3 months
TC; TG; HDL-c; LDL-c;
Creatinine; Urea; Urinary
Microalbumin
Zn acetate;50 mg/day# Melatonin Reduced TC, TG and LDL
Niewoehner et al., [44]
1986, USA
Cohort study; T2DM (n = 13); age 61.0 ±
2.0 year;




# None No beneficial effects observed
Parham et al., [36]
2008, Iran
R, DB, C; T2DM (n = 39); age 53.2 ±
9.2 year;
2 groups; 6 months
FBG; HbA1c; GFR; SBP; DBP;
TC; TG; HDL-c; LDL-c;
Urinary Albumin; Plasma Zinc





R, DB, C; T2DM (n = 27); age 35–
65 year;
2 groups; 4 months
FBG; HbA1c; Plasma Zinc; TG;
TC; LDL-c; HDL-c
ZnSO4;100 mg/day
# None Reduced TC and
TG.Increased HDL
Raz et al., [45]
1989, Israel
Cohort study; T2DM (n = 13); age 55.0 ±
2.4 year;
1 group; 2 months
Plasma Zinc; FBG; Fructosamine;
HbA1c; TC; TG; HDL-c;
immune function; IV GTT
ZnSO4;660 mg/day
# None Increased glucose intolerance
Roussel et al., [46]
2003, Tunisia
R, DB, P; T2DM (n = 56); age 53.6 ±
1.5 year;
2 groups; 6 months
Plasma and Urinary Zinc;
Antioxidant effects
Zn gluconate30 mg/day* None Positive antioxidant effect
Seet et al., [47]
2011, Singapore
R, B, P; T2DM (n = 40); age 56.0 ±
7.5 year;
2 groups; 3 months
FBG; Insulin; TC; LDL-c; HDL-c;
TAG; PAF-AH; PLA2
Zn gluconate;240 mg/day# None No beneficial effects observed
Shidfar et al., [18]
2010, Iran
R, DB, P; T1DM (n = 48); age 7–20 year;
2 groups; 3 months
BMI; Apo A-1 and B; FBG; Insulin ZnSO4;10 mg/day* Vitamin A Increase in serum Apo-A1 and
Decrease in Apo-B/Apo-A1 ratio
ALT-Alanine Aminotransferase; AST-Aspartate Aminotransferase; BMI-Body Mass Index; B-Single blinded; C-Cross over; DB-Double Blinded; FBG-Fasting Blood Glucose; HbA1c-Glycated haemoglobin; HDL-c-High Density
Lipoprotein-Cholesterol; IGF1-Insulin Like Growth Factor-1; IOP-Intra Ocular Pressure; IV GTT-Intravenous Glucose Tolerance Test; LDL-c-Low Density Lipoprotein-Cholesterol; MAP-Mean Arterial Pressure; P-Parallel;
R–Randomized; T1DM-Type 1 Diabetes; T2DM –Type 2 Diabetes; TC-Total Cholesterol; TG-Triglycerides;
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ence for FBG between Zinc supplemented and placebo
groups from random effects analysis was −18.13 mg/dl
(95% CI:–33.85,–2.41; p< 0.05). However statistical het-
erogeneity as indicated by I2 = 99% (p< 0.001) of the data
prevents the evaluation of a pooled estimate for FBG.
The forest plot for 2-h PPBS (n = 4) also shows a similar
distinct reduction in (−34.87 mg/dl [95% CI:–75.44;
5.69]) the Zinc treated group in comparison to controls
(Figure 2b). The reduction in HbA1C (n = 8) was −0.54%















Heterogeneity: Tau² = 756.17; Chi² = 904.63, df = 11 (P < 0.00001); I² = 99

























































































Heterogeneity: Tau² = 1693.37; Chi² = 394.33, df = 3 (P < 0.00001); I² = 99%



















































Heterogeneity: Tau² = 0.19; Chi² = 151.35, df = 7 (P < 0.00001); I² = 95%




































































Figure 2 Forest plots showing effects of Zinc Supplementation on; a)
(2-h PPBS), c) Glycated Haemoglobin (HbA1C) (IV-Inverse variance).comparison to controls (Figure 2c). However statistical
heterogeneity as indicated by I2 = 95% (p< 0.01) prevents
further evaluation of a combined effect. Studies using
Zinc supplement alone also demonstrated similar reduc-
tions in FBG, 2-h PPBS and HbA1c (Additional file 1).
Effects on lipids
The effects of Zinc supplementation on lipids in patients
with type-2 diabetes mellitus was evaluated by pooling data
for TC, LDL-c, HDL-c and TG. There were 8 studies com-
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[19,29,31,33,35-37,47]. The pooled mean difference for TC
between Zinc supplemented and placebo groups from ran-
dom effects analysis was −32.37 mg/dl (95% CI:–57.39,–
7.35; p< 0.05). However statistical heterogeneity as indi-
cated by I299% (p< 0.001) of the data prevents the evalu-
ation of a pooled estimate for TC (Figure 3a). The forest
plot for LDLc also shows a similar distinct reduction in the
Zinc treated group in comparison to controls, the pooled
mean difference from random effects analysis
was11.19 mg/dl (95% CI:–21.14,–1.25; p< 0.05) (Figure 3b).
The pooled mean difference for HDL-c showed an increase
in the Zinc treated group in comparison to controls, how-
ever the overall effect was not significant (Figure 3c). Simi-
larly the overall reduction observed in TG in Zinc
supplemented groups in comparison to controls was not
statistically significant (Figure 3d). Studies using Zinc sup-
plement alone also demonstrated similar reductions in TC,
LDL and TG, and an increase in HDL (Additional file 2).
Other significant effects
Studies have shown a significant reduction in systolic
blood pressure after Zinc supplementation, the reduction
varied from 2.4%–6.1% [19,29,30,36]. Similarly a signifi-
cant reduction in diastolic blood pressure (1.3%–7.1%)
has also being demonstrated in several studies
[19,29,30,36]. Zinc supplementation has shown potential
beneficial antioxidant effects in people with Type 2 Dia-
betes [27]. Increased levels of plasma Thio-Barbituric
Acid Reactive Substances (TBARS) (a marker of lipid
peroxidation) was observed in patients with both type-1
and type-2 diabetes [17,27,46]. Plasma TBARS i.e. lipid
peroxidation decreased significantly after receiving Zn
supplementation in both types of patients [17,27,46]. A
study by Seet et al., using more reliable biomarkers of
oxidative damage (F2-isoprostanes, neuroprostanes, chol-
esterol oxidation products and allantoin) in patients with
type-2 diabetes with normal zinc levels contradicts this
result and show that Zinc supplementation does not
have any impact on oxidative damage and vascular func-
tion [47]. Antioxidant metalloenzyme activity of red cell
Cu-Zn SOD (Super-Oxide Dismutase) was not signifi-
cantly altered [27,46]. However, in type-1 diabetes
patients with retinopathy Zinc supplementation signifi-
cantly increased the activity of Cu-Zn SOD [17]. In
patients with Type 2 Diabetes who had low levels of In-
sulin-like Growth Factor (IGF-1), Zinc supplementation
significantly increased IGF-1 concentrations [38].
Studies evaluating the effects of micronutrients supple-
mentation on various degrees and manifestations of dia-
betic neuropathy have shown that pharmacological
treatment with vitamin C and E, Magnesium and Zinc
supplementation ameliorate severity of neuropathy
symptoms in diabetic patients with mild to moderateperipheral neuropathy [28]. Studies using Zinc supple-
mentations alone have also demonstrated a significant
improvement in motor nerve conduction velocity follow-
ing supplementation in patients with type-2 diabetes
[40,41]. However, autonomic functions have remained
unchanged [40]. Similarly micronutrient supplementa-
tion including vitamins C and E together with Magne-
sium and Zinc significantly lowered urinary albumin
excretion (a marker for glomerular dysfunction) in
patients with type-2 diabetes [29]. In addition, Zinc sup-
plementation alone also reduced albumin excretion in
microalbuminuric patients with type-2 diabetes [36].
Hegazi, et al. reported that Zinc supplementation in
patients with type-2 diabetes improved insulin secretions,
while suppressing glucagon and glucose-6-phosphatase
levels [42]. However, this effect on serum insulin has been
contradicted by other studies [18,33,47]. Furthermore,
Zinc supplementation has resulted in reduced serum
homocysteine concentrations and increased vitamin B12
and folate concentrations in type 2 diabetic patients with
microalbuminuria [43].
Adverse effects
Afkhami-Ardekani et al., reported two cases of mild ab-
dominal pain in patients receiving Zinc sulfate 660 mg/
day for 12 weeks [19]. However, whether they were dir-
ectly attributable to Zinc i.e. a cause-effect relationship
has not been established. There have not been significant
effects on renal and liver functions due to Zinc supple-
mentation, as observed by unchanged blood urea, serum
creatinine levels and plasma AST/ALT levels in those re-
ceiving Zn sulfate (22 mg/day) and Zn acetate (50 mg/
day) for a period of 3–4 months [33,35].
Discussion
This is the first comprehensive systematic review and
meta-analysis of studies evaluating the effects of oral
Zinc supplementation in patients with diabetes mellitus.
We summarize the data from 25 studies, involving a total
of 1,362 patients. Although there is a considerable het-
erogeneity amongst the studies, our data shows several
beneficial metabolic and clinical effects due to Zinc sup-
plementations in patients with diabetes mellitus, namely
improved glycaemic control and lipid parameters, with
probable improvement in anti-oxidant status.
Glycaemic control is one of the most important
therapeutic challenges in present day diabetes care; our
meta-analysis shows that Zinc supplementation causes
significant reduction in FBG, PPBG and HbA1c in patients
with type-2 diabetes. Several molecular mechanisms are
believed to be involved in the regulation of blood glucose
levels following Zinc supplementation. In-vitro and in-vivo
studies have demonstrated the insulin mimetic
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Figure 3 Forest plots showing effects of Zinc Supplementation on; a) Total Cholesterol (TC), b) LDL Cholesterol, c) HDL Cholesterol, d)
Triglycerides (TG) (IV-Inverse variance).
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key regulator of the phosphorylation state of the insulin
receptor is known to be a target of Zinc ions [49]. Studies
have shown that Zinc may play a role in improving
peripheral insulin sensitivity, as it can potentiate insulin-
stimulated glucose transport [50]. It also appears that
Zinc has vital functional roles in β cell physiology [51].
Recent genome wide association studies have found the
islet-restricted Zinc transporter ZnT8 (SLC30A8) as a
potential controller of insulin secretion and hence may
modulate the risks of developing type 2 diabetes [52].
Our results show that post-supplementation HbA1c
values were significantly reduced in the Zinc treated
groups compared with controls. The pooled reduction of
HbA1c was close to −0.6%, a magnitude that is clinically
significant. In the UK Prospective Diabetes Study
(UKPDS), patients randomized to intensive glycaemic
control with Metformin reported a similar reduction of
HbA1c by 0.6% compared to conventional treatment, which
resulted in a 32% risk reduction for diabetes-related clinical
end points and 42% for diabetes-related deaths [53]. How-
ever, as the magnitude of any fall in HbA1c is dependent
upon several factors such as; baseline HbA1C, background
therapy and endogenous β-cell function [54], it is not advis-
able to directly compare the efficacy of Zinc with other glu-
cose lowering agents without the availability of comparable
clinical trial data.
Zinc supplementation resulted in a significant reduc-
tion of plasma total cholesterol, LDL-c and TAG, while
increasing HDL-c levels in patients with type-2 diabetes,
These findings are in contrast to results from a previous
meta-analysis of controlled trials involving healthy sub-
jects, where no beneficial effects of Zinc supplementa-
tion were observed on plasma total cholesterol, LDL-c,
HDL-c or TAG concentrations [55]. The same meta-ana-
lysis showed that Zinc supplementation among healthy
individuals was associated with a significant reduction of
plasma HDL-c concentrations (7% decrease from base-
line) [55]. In contrast to our findings, the above meta-
analysis suggests that Zinc supplementation in healthy
individuals may have detrimental health effects. This re-
lationship between Zinc supplementation in healthy indi-
viduals and HDL-c levels appears to an extent to depend
upon Zinc dosage and duration of supplementation [55].
Serum HDL-c levels appear to decrease at Zinc doses of
over 50 mg/day given for at least three months [56]. In
addition to the lowering of HDL-c by zinc supplementa-
tion in health individuals, several adverse effects are also
reported in the literature. A Randomized Controlled
Trial (RCT) amongst an elderly group reported a signifi-
cantly higher incidence of circulatory adverse effects in
the Zinc supplemented group (80 mg Zn/day), however
the exact nature of these events were not reported [57].
Studies have shown that sustained hyperzincaemia maypredispose individuals to thrombogenesis [56]. The
health professionals follow-up study demonstrated an
increased relatively risk of 2.37 fold for advanced pros-
tate cancer in males who were supplemented with Zinc
more than 100 mg/day [58]. In addition, more than
150 mg of Zinc per day may cause immune dysfunctions
[59]. However, studies have shown that physiological
doses of Zinc supplementation (20 mg/day) for short
durations (2 months) produced favorable effects on nu-
tritional and immune status in marginally Zinc deficient
elderly individuals, while there were no significant
changes observed in the plasma HDL-c levels [60].
Hence, from these findings we can postulate that supple-
menting Zinc may favorably alter lipid metabolism in
patients with diabetes, but not in healthy individuals.
Most of the studies included in the present meta-analysis
were conducted in low-middle income developing coun-
tries where marginal Zinc deficiency might be highly
prevalent, amongst patients with diabetes. Thus, it
appears that the beneficial effects of Zinc supplementa-
tion on metabolic parameters can be seen mainly in indi-
viduals with Zinc deficiency or diseases causing Zinc
deficiency such as diabetes.
Diabetes mellitus is characterized by hyperglycemia to-
gether with biochemical alterations of glucose and lipid
metabolism. Furthermore diabetes results in increased
oxidative stress, which also plays a major role in its’
pathogenesis [61]. In addition to the hypoglycemic and
lipid lowering effects of regular Zinc supplementation in
patients with diabetes, our results show that it reduces
lipid peroxidation and hence demonstrate antioxidant
effects [17,27,46]. Antioxidant properties of Zinc have
long been recognized [62]. Eight weeks of Zinc supple-
mentation in healthy volunteers showed reduction in
plasma levels of lipid peroxidation products, DNA
adducts and reduced mRNA for TNF-α and IL-1β com-
pared to control groups [63]. Oxidative stress and oxida-
tive damage to tissues is known to occur in diabetes and
may be associated with its’ complications. Farvid and
coworkers [28,29] reported beneficial effects on diabetes
neuropathy and nephropathy by Zinc supplementation.
Thus it is possible to hypothesis that reduction in dia-
betes complication may be due to reduction of oxidative
damage from Zinc supplementation. However, all these
studies supplemented other antioxidant vitamins and
minerals together with Zinc, hence it is difficult to con-
clude all these beneficial effects are due to Zinc supple-
ments alone. The effect of Zinc on increasing IGF-1
concentration is mediated at molecular level by the
Zinc/Growth Hormone-receptor complex responsible for
IGF-1 mRNA synthesis, expression and stability [64].
The effect of supplemental Zinc on serum homocysteine
concentration may be due to an influence on methionine
synthase enzyme. Zinc is required for the binding of
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to methionine [43]. Vitamin B12 is formed during this
conversion, which in turn increases tetra-hydro folate
production and hence the increase in Vitamin B12 and
folate following Zinc supplementation.
We acknowledge several limitation to the extent to
which conclusions can be drawn from the present sys-
tematic review. There is a considerable heterogeneity
amongst the included studies, which stems from; a) Var-
iations in baseline parameters such as serum Zinc status,
blood glucose and lipid levels, b) Differences in Zinc
doses, formulae, sample sizes and study durations, and c)
Limited availability of data on Zinc intake from other
sources such as diet. In addition several studies have
supplemented Zinc together with other vitamins and
minerals in a single group, and these vitamins and
minerals could have acted as potential confounding fac-
tors masking/enhancing the isolated effects of Zinc sup-
plementation on diabetes. However, results from studies
using Zinc supplementation alone also show more or less
similar findings and a study that supplemented with
Zinc +MVM (Multi Vitamin Mineral) and MVM with-
out Zinc reported that only patients with diabetes receiv-
ing Zinc +MVM showed beneficial metabolic effects
[33]. Hence, it is reasonable to postulate that these
effects could be the result of Zinc supplementation. Fur-
thermore, studies using Zinc supplement alone also
demonstrated similar beneficial effects on glycaemic con-
trol and lipid parameters (Additional file 1 and 2).
In conclusion, this first comprehensive systematic review
and meta-analysis on the effects of Zinc supplementation
in patients with diabetes demonstrates that Zinc supple-
mentation has beneficial effects on glycaemic control and
promotes healthy lipid parameters. However, individual
studies showed considerable heterogeneity. Further studies
are required to identify the exact biological mechanisms
responsible for these results. In addition, at present there
is only one short-term (4 weeks) study investigating the
effects of Zinc supplementation in pre-diabetes [65].
Hence it is also important to conduct further well design
randomized control trials in those with pre-diabetes to
evaluate potential beneficial effects of Zinc supplementa-
tion in prevention of diabetes.Additional files
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